CareDx Announces Clinical Validation Results for AlloHeme™, the First AI-Powered NGS Surveillance Solution for AML and MDS Post-Cell Therapy
CareDx, Inc. (CDNA)
Last caredx, inc. earnings: 4/30 04:05 pm
Check Earnings Report
US:NASDAQ Investor Relations:
investors.caredxinc.com
Company Research
Source: Business Wire
AlloHeme Identified Cancer Relapse Earlier Than Standard Monitoring Methods in AML and MDS Patients Following Allogeneic HCTUltra-Sensitive, Non-Invasive Surveillance Solution Expected to Launch Commercially in the U.S. in 2027 as Part of CareDx’s Transplant+ Precision Medicine Portfolio BRISBANE, Calif.--(BUSINESS WIRE)--CareDx, Inc. (Nasdaq: CDNA) — The Transplant Company™, a leading precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers, today announced pivotal clinical validation results of AlloHeme™, a non-invasive, next-generation sequencing (NGS)–based, and artificial intelligence (AI)-powered monitoring test designed to predict relapse in patients with acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS) following allogeneic hematopoietic cell transplant (HCT). This approach enables the detection of emerging relapse signals earlie
Show less
Read more
Impact Snapshot
Event Time:
CDNA
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
CDNA alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
CDNA alerts
High impacting CareDx, Inc. news events
Weekly update
A roundup of the hottest topics
CDNA
News
- CareDx to Report Fourth Quarter and Full Year 2025 Financial Results on February 24, 2026Business Wire
- CareDx to Present AlloHeme™ Pivotal Clinical Validation Data in Hematologic Cancer Relapse Detection at 2026 Tandem Meetings [Yahoo! Finance]Yahoo! Finance
- CareDx to Present AlloHeme™ Pivotal Clinical Validation Data in Hematologic Cancer Relapse Detection at 2026 Tandem MeetingsBusiness Wire
- CareDx's CEO Conducts Multiple Sale of Shares Towards the End of January 2026 [Yahoo! Finance]Yahoo! Finance
- Did Strong 2025 Revenue Growth and 10x Genomics Deal Just Shift CareDx's (CDNA) Investment Narrative? [Yahoo! Finance]Yahoo! Finance
CDNA
Earnings
- 11/4/25 - Beat
CDNA
Sec Filings
- 2/9/26 - Form SCHEDULE
- 2/4/26 - Form 4
- 2/4/26 - Form 4
- CDNA's page on the SEC website